ATE431148T1 - Verwendung von cyclischen bioisosteren von purin- system-derivaten zur behandlung von erkrankungen durch störungen der nitrergen und dopaminergen systeme - Google Patents

Verwendung von cyclischen bioisosteren von purin- system-derivaten zur behandlung von erkrankungen durch störungen der nitrergen und dopaminergen systeme

Info

Publication number
ATE431148T1
ATE431148T1 AT04775242T AT04775242T ATE431148T1 AT E431148 T1 ATE431148 T1 AT E431148T1 AT 04775242 T AT04775242 T AT 04775242T AT 04775242 T AT04775242 T AT 04775242T AT E431148 T1 ATE431148 T1 AT E431148T1
Authority
AT
Austria
Prior art keywords
nitrergic
treatment
bioisosters
disorders
cyclic
Prior art date
Application number
AT04775242T
Other languages
English (en)
Inventor
Valery Khazhmuratovich Zhilov
Sergei Vladimirovich Zhuravlev
Alexandr Nikolaevich Markov
Vladimir Mikhailovich Polosin
Original Assignee
Valery Khazhmuratovich Zhilov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valery Khazhmuratovich Zhilov filed Critical Valery Khazhmuratovich Zhilov
Application granted granted Critical
Publication of ATE431148T1 publication Critical patent/ATE431148T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
AT04775242T 2003-08-04 2004-08-03 Verwendung von cyclischen bioisosteren von purin- system-derivaten zur behandlung von erkrankungen durch störungen der nitrergen und dopaminergen systeme ATE431148T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/RU2003/000346 WO2005012309A1 (en) 2003-08-04 2003-08-04 Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
PCT/RU2004/000298 WO2005011648A2 (en) 2003-08-04 2004-08-03 Use of cyclic bioisosteres of purine system derivatives for the treatment diseases caused by disorders of nitrergic and dopaminergic systems

Publications (1)

Publication Number Publication Date
ATE431148T1 true ATE431148T1 (de) 2009-05-15

Family

ID=34114562

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04775242T ATE431148T1 (de) 2003-08-04 2004-08-03 Verwendung von cyclischen bioisosteren von purin- system-derivaten zur behandlung von erkrankungen durch störungen der nitrergen und dopaminergen systeme

Country Status (7)

Country Link
US (2) US8592421B2 (de)
EP (3) EP1655301B1 (de)
AT (1) ATE431148T1 (de)
AU (1) AU2003301513A1 (de)
DE (1) DE602004021114D1 (de)
UA (1) UA85389C2 (de)
WO (2) WO2005012309A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL231885B1 (pl) * 2009-01-16 2019-04-30 Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
PL2542535T3 (pl) 2010-03-01 2014-10-31 Metriopharm Ag Formy krystaliczne soli sodowej 5-amino-2,3-dihydroftalazyno-1,4-dionu, kompozycje farmaceutyczne je zawierające i sposoby ich wytwarzania
US9398642B2 (en) 2012-10-22 2016-07-19 Thales Canada Inc Removable heater for communication antenna
US9901342B2 (en) 2015-03-06 2018-02-27 Ethicon Endo-Surgery, Llc Signal and power communication system positioned on a rotatable shaft

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5046697A (de) 1973-08-20 1975-04-25
US4727079A (en) * 1983-01-27 1988-02-23 University Of Florida Brain-specific dopaminergic activity involving dihydropyridine carboxamides, dihydroquinoline and isoquinoline carboxamides
IL69132A (en) * 1982-07-14 1986-02-28 Roussel Uclaf Benzo-and naphtho-thiopyranopyrimidinones,their preparation and pharmaceutical compositions containing them
SE8302361D0 (sv) * 1983-04-27 1983-04-27 Astra Laekemedel Ab New tricyclic amines
US4548817A (en) * 1984-01-20 1985-10-22 Webb-Waring Lung Institute Composition and method for treating mammalian acidosis
US4600714A (en) * 1984-04-26 1986-07-15 Smithkline Beckman Corporation Fenoldopam 4',8-bis-hydrogen sulfate and dopaminergic use thereof
US4650805A (en) * 1985-12-02 1987-03-17 Warner-Lambert Company 4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and 4-(hexahydro-1-alkyl-3-pyridinyl)-2-thiazolamines having anti-psychotic activity
GB8610432D0 (en) * 1986-04-29 1986-06-04 Akzo Nv Amino-thiazole & oxazole derivatives
US4950602A (en) * 1987-02-20 1990-08-21 Cornell Research Foundation, Inc. Inhibition of lactate production by pyruvate adducts
RU2014077C1 (ru) 1987-10-26 1994-06-15 Одесский научно-исследовательский институт стоматологии Средство для интегральной коррекции метаболического ацидоза и алколоза
US5256660A (en) 1987-12-14 1993-10-26 Henry Swan Ii Trust Synthetic buffer composition for clinical use
CA1321751C (en) 1989-02-21 1993-08-31 Eugene C. Crichlow Mechanism mediating ruminal stasis in ruminal lactic acidosis
US5719151A (en) 1990-05-04 1998-02-17 Shall; Sydney Substituted benzene compounds
JPH05507933A (ja) * 1990-06-29 1993-11-11 ジ・アップジョン・カンパニー Ｃｎｓおよび抗高血圧活性を有する置換１―（アルコキシフェニル）ピペラジン類
JP3167762B2 (ja) 1990-11-27 2001-05-21 武田薬品工業株式会社 ピリドピリダジン誘導体およびその用途
US5723496A (en) 1991-03-05 1998-03-03 The Regents Of University Of California Method for prevention and treatment of harmful effects of intracellular acidosis
CH683965A5 (it) 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
CH683966A5 (it) 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanze attive in agenti anti-ipossici e di difesa.
IL111266A (en) 1993-10-22 2002-03-10 Zeneca Ltd 2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5476855A (en) * 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
TW372967B (en) * 1994-12-27 1999-11-01 Kanebo Ltd 1,4 benzoxazine derivative, pharmaceutical composition containing the same and use thereof
US5883094A (en) * 1995-04-24 1999-03-16 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
RU2108806C1 (ru) 1995-05-10 1998-04-20 Юсупов Салехжан Загидуллович Способ коррекции иммунной системы
RU2098086C1 (ru) 1995-05-10 1997-12-10 Муса Тажудинович Абидов Способ диагностики онкологических заболеваний
US5889010A (en) * 1995-05-18 1999-03-30 Pfizer Inc. Benzimidazole derivatives having dopaminergic activity
US5753706A (en) 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
EP1004304A4 (de) * 1996-12-24 2002-10-16 Sumitomo Pharma Zusammensetzung mit acorbinsäure
GB9707693D0 (en) * 1997-04-16 1997-06-04 Smithkline Beecham Plc Novel method of treatment
RU2113222C1 (ru) 1997-09-30 1998-06-20 Закрытое акционерное общество "Центр современной медицины "Медикор" Иммуномодулирующее средство
RU2160104C2 (ru) 1997-11-06 2000-12-10 Закрытое акционерное общество "Центр современной медицины "Медикор" Способ лечения язвенной болезни и лекарственный препарат для его осуществления
RU2132189C1 (ru) 1998-11-03 1999-06-27 Закрытое акционерное общество "Абидофф-Фарма" Способ лечения мастопатии и миомы матки
RU2132685C1 (ru) 1998-11-03 1999-07-10 Закрытое акционерное общество "Абидофф-Фарма" Способ лечения доброкачественной гиперплазии предстательной железы
RU2132188C1 (ru) 1998-11-03 1999-06-27 Закрытое акционерное общество "Абидофф-Фарма" Способ лечения гипофункции щитовидной железы
RU2138264C1 (ru) 1999-05-06 1999-09-27 Абидов Муса Тажудинович Способ получения лекарственного препарата галавит
RU2155043C1 (ru) 2000-03-28 2000-08-27 Абидов Муса Тажудинович Способ получения лекарственного препарата
RU2163122C1 (ru) 2000-08-01 2001-02-20 Абидов Муса Тажудинович Лекарственное средство
ATE473743T1 (de) 2000-03-28 2010-07-15 Musa Tazhudinovich Abidov Arzneimittel und dessen herstellungsprozess
RU2167659C1 (ru) 2000-08-02 2001-05-27 Закрытое акционерное общество "Центр современной медицины "Медикор" Способ коррекции иммунной системы живого организма
RU2169139C1 (ru) 2000-08-02 2001-06-20 Закрытое акционерное общество "Центр современной медицины "Медикор" Способ получения щелочных и щелочноземельных солей 5-амино-2,3-дигидро-1,4-фталазиндиона
US6521623B1 (en) * 2000-09-19 2003-02-18 Boehringer Ingelheim Pharma Kg N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
RU2185173C2 (ru) 2000-09-20 2002-07-20 Государственный институт кровезаменителей и медицинских препаратов Препарат гемодинамического действия с функцией нормализации кислотно-основного равновесия и электролитного баланса
RU2211036C2 (ru) 2001-11-20 2003-08-27 Общество с ограниченной ответственностью "Абидофарма" Лекарственный препарат (варианты) и способ его производства
US6953799B1 (en) * 2002-10-30 2005-10-11 Bach Pharma, Inc. Modulation of cell fates and activities by diketo phthalazines

Also Published As

Publication number Publication date
EP1655301A4 (de) 2007-09-19
US20080194501A1 (en) 2008-08-14
EP2074998A2 (de) 2009-07-01
AU2003301513A1 (en) 2005-02-15
EP1655301B1 (de) 2015-03-11
WO2005012309A1 (en) 2005-02-10
EP1655301A1 (de) 2006-05-10
US20070135636A1 (en) 2007-06-14
EP1655028A2 (de) 2006-05-10
US7776833B2 (en) 2010-08-17
EP2074998B1 (de) 2013-10-16
EP2074998A3 (de) 2009-10-07
EP1655028B1 (de) 2009-05-13
WO2005011648A2 (en) 2005-02-10
US8592421B2 (en) 2013-11-26
WO2005011648A3 (fr) 2005-08-04
UA85389C2 (ru) 2009-01-26
DE602004021114D1 (de) 2009-06-25

Similar Documents

Publication Publication Date Title
ATE411280T1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
ATE432072T1 (de) Verwendung von adapalen zur behandlung dermatologischer erkrankungen
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
ES2282685T3 (es) Derivados de hidroxietilamina para el tratamiento de la enfermedad de alzheimer.
BR0308937A (pt) Compostos imidazo fundidos
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
UY27976A1 (es) Piperazinas heterocíclicas sustituídas para el tratamiento de la esquizofrenia
BR0312729A (pt) Novos derivados de indol-3-enxofre
BRPI0409109A (pt) novos compostos
BR0113039A (pt) Composto ou um seu sal ou solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica em aerossol, método para o tratamento de um indivìduo humano ou animal com uma condição antiinflamatória e/ou alérgica, e, processo para preparar um composto
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
BR0311494A (pt) Novos indóis substituìdos
CL2003002683A1 (es) Enantiomeros s de compuestos derivados del acido (2s)-3-4(-{2-amino-2-oxoetoxi}fenil)-2-etoxipropanoico; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos de lipidos,
DE60226729D1 (de) Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
AR041298A1 (es) Derivados de pirrolidona como inhibidores de maob
BR0307574A (pt) Derivados de nicotinamida úteis como inibidores de pde4
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
BRPI0408727A (pt) composto, processo para preparar o mesmo, composição farmacêutica, método para tratar de uma condição ou estado de doença mediados pela atividade da quinase p38 ou mediados pelas citocinas produzidas pela atividade da quinase p38, e, uso de um composto
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
BRPI0410837A (pt) composto, composição farmacêutica, e, método para tratar ou prevenir uma doença ou condição
HRP20050741A2 (en) 1,3-substituted cycloalkyl containing acidic, mainly heterocyclic groups, corresponding production method and use of said derivatives as medicaments
ATE431148T1 (de) Verwendung von cyclischen bioisosteren von purin- system-derivaten zur behandlung von erkrankungen durch störungen der nitrergen und dopaminergen systeme

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties